Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
Srđan Verstovšek(Unknown), Claire Harrison(National Health Service), David Lavie(Hadassah Medical Center), Aaron T. Gerds(Cleveland Clinic), Tomasz Sacha, Marek Hus(Medical University of Lublin), Jun Kawashima(Gunma University), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Viviane Dubruille(Centre Hospitalier Universitaire de Nantes), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Miklós Egyed, Jiřı́ Mayer(Masaryk University), Nathalie Cambier, Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Vikas Gupta(Indian Institute of Technology Kanpur), Uwe Platzbecker(National Center for Tumor Diseases), Marc Morris, Stephen T. Oh(Washington University in St. Louis), Mei Huang, Jean‐Jacques Kiladjian(Délégation Paris 5)
Cited by 48
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k